Intraocular pressure-lowering efficacy of dorzolamide/timolol fixed combination in normal-tension glaucoma

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

PURPOSE:: To investigate the intraocular pressure (IOP)-lowering efficacy and safety of dorzolamide/timolol fixed combination (DTFC) in patients with normal-tension glaucoma (NTG). METHODS:: An open-label, 12-week, 2-center study was conducted. Thirty-seven patients with treatment-naïve NTG received DTFC for 12 weeks to reduce IOP. Primary outcome measures were changes in IOP from baseline to 12 weeks of treatment at a peak drug effect. Secondary outcome measures were changes in IOP from baseline to 12 weeks of treatment a trough drug effect and 8 hours after drug administration. At each visit, IOP was measured at 9 AM and then DTFC was administered by a hospital personnel. IOP was also measured at 11 AM and 5 PM At week 12, the IOP was measured at 1 and 3 PM as well. RESULTS:: The IOP at peak drug effect (11 AM) at 12 weeks was significantly reduced to 11.9±2.6 mm Hg from the baseline of 15.6±2.5 mm Hg (23.7%, P<0.0001). Significant reduction in the IOP was also achieved at trough drug effect (9 AM) and at 8 hours after drug administration (5 PM) at 12 weeks (20.5% and 24.4%, respectively, all P<0.0001). Eye irritation (59.5%) was the most frequently reported adverse event followed by ocular hyperemia (16.2%). The majority of eye irritations were mild in intensity. No patients discontinued the DTFC due to an adverse event and no systemic adverse event was considered related to study medication. CONCLUSIONS:: DTFC is a safe and effective IOP-lowering agent in patients with NTG.

Original languageEnglish
Pages (from-to)329-332
Number of pages4
JournalJournal of Glaucoma
Volume23
Issue number5
DOIs
StatePublished - 1 Jan 2014

Fingerprint

Low Tension Glaucoma
Intraocular Pressure
Pharmaceutical Preparations
Outcome Assessment (Health Care)
dorzolamide-timolol combination
Hospital Personnel
Hyperemia
Proxy
Therapeutics

Keywords

  • Dorzolamide/timolol fixed combination
  • Efficacy
  • Intraocular pressure
  • Normal-tension glaucoma
  • Safety

Cite this

@article{db91a974e34d4a988131cab1d29b5819,
title = "Intraocular pressure-lowering efficacy of dorzolamide/timolol fixed combination in normal-tension glaucoma",
abstract = "PURPOSE:: To investigate the intraocular pressure (IOP)-lowering efficacy and safety of dorzolamide/timolol fixed combination (DTFC) in patients with normal-tension glaucoma (NTG). METHODS:: An open-label, 12-week, 2-center study was conducted. Thirty-seven patients with treatment-na{\"i}ve NTG received DTFC for 12 weeks to reduce IOP. Primary outcome measures were changes in IOP from baseline to 12 weeks of treatment at a peak drug effect. Secondary outcome measures were changes in IOP from baseline to 12 weeks of treatment a trough drug effect and 8 hours after drug administration. At each visit, IOP was measured at 9 AM and then DTFC was administered by a hospital personnel. IOP was also measured at 11 AM and 5 PM At week 12, the IOP was measured at 1 and 3 PM as well. RESULTS:: The IOP at peak drug effect (11 AM) at 12 weeks was significantly reduced to 11.9±2.6 mm Hg from the baseline of 15.6±2.5 mm Hg (23.7{\%}, P<0.0001). Significant reduction in the IOP was also achieved at trough drug effect (9 AM) and at 8 hours after drug administration (5 PM) at 12 weeks (20.5{\%} and 24.4{\%}, respectively, all P<0.0001). Eye irritation (59.5{\%}) was the most frequently reported adverse event followed by ocular hyperemia (16.2{\%}). The majority of eye irritations were mild in intensity. No patients discontinued the DTFC due to an adverse event and no systemic adverse event was considered related to study medication. CONCLUSIONS:: DTFC is a safe and effective IOP-lowering agent in patients with NTG.",
keywords = "Dorzolamide/timolol fixed combination, Efficacy, Intraocular pressure, Normal-tension glaucoma, Safety",
author = "Kim, {Tae Woo} and Martha Kim and Lee, {Eun Ji} and Jeoung, {Jin Wook} and Park, {Ki Ho}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/IJG.0b013e3182741f4d",
language = "English",
volume = "23",
pages = "329--332",
journal = "Journal of glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "5",

}

TY - JOUR

T1 - Intraocular pressure-lowering efficacy of dorzolamide/timolol fixed combination in normal-tension glaucoma

AU - Kim, Tae Woo

AU - Kim, Martha

AU - Lee, Eun Ji

AU - Jeoung, Jin Wook

AU - Park, Ki Ho

PY - 2014/1/1

Y1 - 2014/1/1

N2 - PURPOSE:: To investigate the intraocular pressure (IOP)-lowering efficacy and safety of dorzolamide/timolol fixed combination (DTFC) in patients with normal-tension glaucoma (NTG). METHODS:: An open-label, 12-week, 2-center study was conducted. Thirty-seven patients with treatment-naïve NTG received DTFC for 12 weeks to reduce IOP. Primary outcome measures were changes in IOP from baseline to 12 weeks of treatment at a peak drug effect. Secondary outcome measures were changes in IOP from baseline to 12 weeks of treatment a trough drug effect and 8 hours after drug administration. At each visit, IOP was measured at 9 AM and then DTFC was administered by a hospital personnel. IOP was also measured at 11 AM and 5 PM At week 12, the IOP was measured at 1 and 3 PM as well. RESULTS:: The IOP at peak drug effect (11 AM) at 12 weeks was significantly reduced to 11.9±2.6 mm Hg from the baseline of 15.6±2.5 mm Hg (23.7%, P<0.0001). Significant reduction in the IOP was also achieved at trough drug effect (9 AM) and at 8 hours after drug administration (5 PM) at 12 weeks (20.5% and 24.4%, respectively, all P<0.0001). Eye irritation (59.5%) was the most frequently reported adverse event followed by ocular hyperemia (16.2%). The majority of eye irritations were mild in intensity. No patients discontinued the DTFC due to an adverse event and no systemic adverse event was considered related to study medication. CONCLUSIONS:: DTFC is a safe and effective IOP-lowering agent in patients with NTG.

AB - PURPOSE:: To investigate the intraocular pressure (IOP)-lowering efficacy and safety of dorzolamide/timolol fixed combination (DTFC) in patients with normal-tension glaucoma (NTG). METHODS:: An open-label, 12-week, 2-center study was conducted. Thirty-seven patients with treatment-naïve NTG received DTFC for 12 weeks to reduce IOP. Primary outcome measures were changes in IOP from baseline to 12 weeks of treatment at a peak drug effect. Secondary outcome measures were changes in IOP from baseline to 12 weeks of treatment a trough drug effect and 8 hours after drug administration. At each visit, IOP was measured at 9 AM and then DTFC was administered by a hospital personnel. IOP was also measured at 11 AM and 5 PM At week 12, the IOP was measured at 1 and 3 PM as well. RESULTS:: The IOP at peak drug effect (11 AM) at 12 weeks was significantly reduced to 11.9±2.6 mm Hg from the baseline of 15.6±2.5 mm Hg (23.7%, P<0.0001). Significant reduction in the IOP was also achieved at trough drug effect (9 AM) and at 8 hours after drug administration (5 PM) at 12 weeks (20.5% and 24.4%, respectively, all P<0.0001). Eye irritation (59.5%) was the most frequently reported adverse event followed by ocular hyperemia (16.2%). The majority of eye irritations were mild in intensity. No patients discontinued the DTFC due to an adverse event and no systemic adverse event was considered related to study medication. CONCLUSIONS:: DTFC is a safe and effective IOP-lowering agent in patients with NTG.

KW - Dorzolamide/timolol fixed combination

KW - Efficacy

KW - Intraocular pressure

KW - Normal-tension glaucoma

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84902274129&partnerID=8YFLogxK

U2 - 10.1097/IJG.0b013e3182741f4d

DO - 10.1097/IJG.0b013e3182741f4d

M3 - Article

C2 - 23377586

AN - SCOPUS:84902274129

VL - 23

SP - 329

EP - 332

JO - Journal of glaucoma

JF - Journal of glaucoma

SN - 1057-0829

IS - 5

ER -